Joint Project Team. As soon as possible after the Effective Date, the Parties shall establish a joint project team (the “JPT”) which shall be initially responsible for the day-to-day operations of the Initial Target Program. The JPT shall also be responsible for the day-to-day operations of all other Collaboration Programs when they become ***Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. effective; provided, that if multiple JPTs are needed due to different Targets or disease areas, then the Parties may establish separate JPTs for different Collaboration Programs. The JPT shall be comprised of representatives from each of GSK and Adaptimmune with the appropriate scientific expertise with respect to the conduct of the Development Plans (and such representatives may vary depending on the relevant Project Phase) and shall meet on a monthly basis (or more or less frequently as agreed by the Parties) at Adaptimmune’s facilities, GSK’s facilities or via teleconference at such times as may be agreed by the Parties during the term of the applicable Collaboration Program. The JPT will report to the JSC and will be responsible for the day-to-day management of the conduct of the Development Plans including any non-material changes to the Development Plans, overseeing the conduct of experiments and reviewing data resulting from such experiments as set forth in the Development Plans, proposing amendments to the Development Plans, proposing new Development Plans to the JSC for new Collaboration Programs for JSC approval, discussing potential Lead Candidates and Development Candidates for proposal to the JSC. All decisions of the JPT on matters for which it has responsibility shall be made unanimously. In the event that the JPT is unable to reach a unanimous decision within ten (10) Business Days after it has met and attempted to reach such decision, then either Party may, by written notice to the other, have such issue submitted to the JSC for resolution in accordance with Section 4.5. Each Party will bear all expenses it incurs in regard to participating in all meetings of the JPT, including all travel and living expenses. Each JPT shall automatically cease to exist on completion of the relevant Collaboration Programs that it supports and exercise or expiry of all Collaboration Program Options applicable to such Collaboration Programs.
Joint Project Team. The Parties hereby establish a joint project team (the “Joint Project Team” or “JPT”) to develop and propose plans to governing committees, manage operational activities and serve as an information resource for the Committees. The members of the JPT representing core functions relevant to the joint development and commercialization of Products (the “Core Joint Project Team” or “Core JPT”) shall provide oversight to the overall JPT. Until such time as when the JDC and the JCC have been formed, the Core JPT shall have the additional responsibilities set out in Schedule G(a) and G(b), respectively. Neither the JPT nor the Core JPT will have any decision-making authority, except as set out in Schedule G(a) or G(b) or otherwise explicitly authorized by an appropriate Committee. The Parties agree to establish a JPT Charter on or prior to October 31, 2014, which contains the composition and responsibilities of the JPT and the Core JPT. Subject to the JPT Charter, the Core JPT will consist of project leaders as appointed by FibroGen and by AstraZeneca, and such additional members as the Parties deem appropriate from time to time. Each Party will appoint appropriately qualified and authorized representatives for each applicable operational area or function. The JPT members will serve as the point of contact for operational matters between the Parties. The JPT may form subteams to support the efforts of the JPT as agreed by the Parties. As appropriate, FibroGen may arrange, on its own initiative or at AstraZeneca’s reasonable request from time to time, a joint meeting between the JPT and the project team under the Astellas Collaboration.
Joint Project Team. Within […***…] following dissolution of the JSC, the Parties agree to form a joint project team (the “Joint Project Team” or “JPT”). The JPT’s purpose will be to facilitate the exchange of information with respect to (a) the commercialization, including reimbursement strategies, regarding the Licensed GT Product and Licensed Treatment and Dimension’s gene therapy products, in particular, in the field of Hemophilia B, and (b) the continued clinical development of the Licensed GT Product post *** Confidential Treatment Requested *** Regulatory Approval. The JPT shall meet at least every […***…] either telephonically or in person, unless the Parties mutually agree in writing to a different frequency for such meetings. For clarity, the JPT functions primarily as an information exchange forum and does not affect any decision-making discretion or right that Bayer otherwise possesses under this Agreement.
Joint Project Team. In connection with commencing R&D Activities with respect to a given project, the Joint Steering Committee shall form a Joint Project Team for such project. Each Joint Project Team shall be composed of employees from AMYRIS and Seconded Employees (the number of FTEs to be set by the Joint Steering Committee at any given time based on ongoing activities, and the individual employees, to be proposed by the employer-Party and approved by the Joint Steering Committee) and shall be located at AMYRIS Laboratory Facilities, as appropriate to the work to be performed. The Parties shall allocate competent employees to work on each Joint Project Team with relevant competencies, skills and experience. Each Joint Project Team shall be responsible with respect to the applicable project for:
Joint Project Team. The Parties hereby establish a JPT to facilitate the Research Program as follows:
Joint Project Team. The Development and Commercialization activities and Legal Activities shall be conducted and managed on a day-to-day basis through a Joint Project Team ("JOINT PROJECT TEAM" or "JPT"). Momenta and Sandoz shall each appoint one (1) Project Leader promptly following the Effective Date and may change its Project Leader at any time by giving written notice to the other. The JPT shall consist of three (3) (or such other mutually agreed number) representatives from each of Sandoz and Momenta (including each Party's then-current Project Leader), which representatives shall be directly involved with and responsible for Development and Commercialization activities and Legal Activities. Promptly after the Effective Date, Momenta and Sandoz shall each appoint its representatives to the JPT. Momenta and Sandoz may each change its JPT representatives at any time by giving written notice to the other. The JPT shall meet within thirty (30) days after the Effective Date and, thereafter, at least quarterly during the course of the Collaborative Program. Additional representatives of a Party may attend meetings of the JPT on an AD HOC invited basis as appropriate.
Joint Project Team. [***] after the Effective Date, the JRC shall establish a Subcommittee (the "Joint Project Team" or "JPT") to oversee the conduct of the Research Collaboration with respect to [***]. The JPT shall be comprised of an equal number of representatives from each of GSK and Anacor and shall meet on such dates and at such places and times agreed to by the Parties. All decisions of the JPT on matters for which it has responsibility shall be made by consensus, with each Party having collectively one (1) vote in all decisions. In the event that the JPT is unable to reach a consensus decision within [***] after it has met and attempted to reach such decision, then either Party may, by written notice to the other, have such issue submitted to the JRC for resolution in accordance with Section 3.1.4 and 3.1.4(a). Each Party will bear all expenses it incurs in regard to participating in all meetings of the JPT, including all travel and living expenses.
Joint Project Team. No later than [***] following the Effective Date, the JSC will form a joint project team (the “JPT”) to coordinate and oversee the day-to-day performance of the activities and obligations of the Parties under this Agreement. The JPT will be composed of representatives from each Party who have direct knowledge and expertise in each of the following functional areas: clinical, clinical operations, pharmaceutical development, regulatory, safety, manufacturing, intellectual property, marketing and commercial, in each case, as such functional areas relate to products similar to Licensed Products; provided that [***] of Zai’s representatives in the JPT shall be fluent in English. The JPT shall meet as frequently as and shall operate as the JSC may determine. The JPT may meet in person or by means of teleconference, Internet conference, videoconference or other similar communications method. The JPT and its activities shall be subject to the oversight of, and shall report to, the JSC and the JSC shall resolve all disputes that arise within the JPT within [***] after any such matter is brought to the JSC for resolution. In no event shall the authority of the JPT exceed the authority of the JSC. Each Party shall be responsible for all of its own expenses of participating in the JPT.
Joint Project Team. (a) The Discovery Phase of the Program will be managed by a Joint Project Team. DuPont and 3DP will each designate three (3) members selected by their respective R&D management to form this Joint Protect Team. The Joint Project Team shall be responsible for:
Joint Project Team. (a) The Parties shall establish a Joint Project Team which shall meet at least [**] times per Year [**], or more frequently as the Parties deem necessary, to ensure the technical and regulatory development of the Licensed Product under this Agreement will be timely and cooperatively executed. Such meetings of Joint Project Team shall be held at times and dates and on the locations as are mutually agreed. Each Party shall have the responsibility to supply or assign appropriate personnel and all relevant data and other information needed to implement and accomplish the obligations set forth below in Article 2.5(b).